Flatlander schreef op 19 augustus 2019 23:02:
I do see an inflection point in the growth trajectory in 2020.. I believe the growth will increase for the following reasons:
Onco Dx Breast cancer test is the equivalent of a killer Ap. It has substantial documentation as being the only test to determine whether a woman with Breast cancer will benefit from chemotherapy. this test should start launching on Idylla in the EU in mid 2020. A similar inflection point occurred for GHDX when the TailorX study was released.
BCART has started initial negotiations w the FDA to receive approval for idylla in diagnostic use. with the help of partners (primarily Amgen and BMS) this approval can occur in 2020 and would open the door for insurance reimbursement and broader usage in the US. S second phase of growth will occur when small hospitals and clinics realize that they can price the test very profitably.
The china agreement with Wonfu occurred about a year ago. They have had time to work with regulators to validate the platform. I suspect in the next couple months that we will hear about a Chinese manufacturing facility and the strategy to ramp up sales in China. This growth in the largest market in the world will occur on a zero base.
Similarly, a Japan update should provide more information on sales expansion in that market.
If my inflection point assumptions are correct, I believe BCART could hit break even during late 2020 or early 2021.